Multidrug resistance associated protein 1 protects against bilirubin-induced cytotoxicity  by Calligaris, Sebastián et al.
FEBS Letters 580 (2006) 1355–1359Multidrug resistance associated protein 1 protects against
bilirubin-induced cytotoxicity
Sebastia´n Calligarisa,b, Dean Cekica,b, Leslye Roca-Burgosa,b, Fabio Gerina,b,
Graciela Mazzonea,b, J. Donald Ostrowc, Claudio Tiribellia,b,*
a Centro Studi Fegato, Bld Q, AREA Science Park, Basovizza Campus, ss 14 Km 163.5, 34012 Trieste, Italy
b Department BBCM, University of Trieste, 34012 Trieste, Italy
c GI/Hepatology Division, University of Washington, Seattle, WA 98195, USA
Received 9 December 2005; revised 18 January 2006; accepted 19 January 2006
Available online 26 January 2006
Edited by Maurice MontalAbstract We have shown that multidrug resistance associated
protein 1 (MRP1) mediates ATP-dependent extrusion of biliru-
bin, possibly limiting its potentially toxic accumulation in cells.
To determine directly if Mrp1 protects cells against unconju-
gated bilirubin (UCB) toxicity, mouse embryo ﬁbroblasts
(MEF) were isolated from Mrp1 knockout (/) mice and their
wild type (WT) (+/+) littermates. Compared to WT cells, cul-
tured MEF (/) cells exposed to 40–140 nM unbound [H3]-bil-
irubin accumulated twice as much [H3]-bilirubin (P < 0.01). This
was associated with greater, dose-related cytotoxicity, assessed
by the methylthiazoletetrazolium test, lactate dehydrogenase re-
lease and cellular ATP content. The data conﬁrm that Mrp1 lim-
its intracellular accumulation of UCB and thus decreases its
cytotoxicity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.1. Introduction
Multidrug-resistance-associated protein 1 (Mrp1) was the
ﬁrst identiﬁed member of the MRP/Mrp subfamily of ATP-
binding-cassette (ABC) transporters [1]. Increased expression
of Mrp1 was correlated with the development of multidrug
resistance by cells previously sensitive to chemotherapy [2].
Mrp1 can transport many exogenous agents, such as chemo-
therapeutics (daunorubicin, etoposide and vincristine) [3], met-
alloid salts (antimony and arsenic) [4] and aﬂatoxin B1 [5].
Mrp1 also transports endogenous compounds such as arachi-
donic acid derivatives (leukotriene C4 is the highest aﬃnity
substrate), glutathione conjugates, glucuronide and sulfate
conjugates of bile salts, GSSG, 17b-estradiol 17-(b-D-glucuro-
nide) and bilirubin glucuronides [6].Abbreviations: UCB, unconjugated bilirubin; Bf, unbound UCB con-
centration; MRP1/Mrp1, Multidrug resistance associated protein 1;
HSA, human serum albumin; DMEM/high, Dulbecco’s modiﬁed Ea-
gle’s high glucose medium; LDH, lactate dehydrogenase; MEF, mouse
embryo ﬁbroblasts; MTT, methylthiazoletetrazolium
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doi:10.1016/j.febslet.2006.01.056Mrp1, and another multidrug resistance protein (MDR1)
which shares many of the substrates transported by Mrp1,
are both expressed in blood–brain barriers, where they play
important roles in limiting accumulation, in the cerebrospi-
nal ﬂuid and central nervous system (CNS), respectively,
of a wide variety of xeno- and endo-biotics [7]. Of great
importance among the latter is unconjugated bilirubin
(UCB), which is toxic to CNS cells at high concentrations
[8] and is responsible for the increasing prevalence of biliru-
bin-induced encephalopathy in severely jaundiced newborns
[9]. Our laboratory has previously shown a pivotal role of
Mrp1 in the cellular export of UCB. Petrovic et al. found
that UCB is a substrate for both YCF1and YLL015 gene
products in Saccharomyces cerevisiae, two ABC transporters
that are highly homologous with human Mrp1 [10]. Pascolo
et al. observed that BeWo cells, grown in Transwells, con-
comitantly increase the export of UCB and the expression of
Mrp1 with increased polarization [11]. Moreover, the induc-
tion of hyperhemolysis, by injection of rats with phenylhydr-
azine, increases the levels of blood bilirubin and
concomitantly induces increased levels of Mrp1 in liver
and spleen [12]. Finally, Rigato et al. [13] measured the up-
take of [3H]-UCB in plasma membrane vesicles of MDCK II
cells and showed an increased accumulation of bilirubin in
vesicles derived from cells transfected with human MRP1,
compared with mock-transfected wild type (WT) cells. Ta-
ken together, these results indicate that UCB is transported
by MRP1/Mrp1.
This suggests that MRP1/Mrp1 might play an important
role in protecting cells from toxic accumulation of UCB.
By confocal immunoﬂuorescence microscopy, Gennuso
et al. demonstrated that exposure of mouse astroglial cells
to increased levels of bilirubin induced a very rapid increase
of Mrp1 signal, and its translocation from the Golgi to the
cell membrane [14]. These authors showed also that inhibi-
tion of Mrp’s with MK-571 increased the cellular toxicity
of bilirubin, but this inhibitor is not speciﬁc for Mrp1,
and its eﬀect on bilirubin uptake was not evaluated. In the
present study we compared the cellular accumulation of
[3H]-bilirubin by mouse embryo ﬁbroblasts (MEF) isolated
from animals that lack the genetic expression of Mrp1 and
their WT littermates. We also studied the dose-related rela-
tionship between cellular accumulation of UCB and the
cytotoxic eﬀects of bilirubin.blished by Elsevier B.V. All rights reserved.
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2.1. Animals
Mrp1 (/) mice were generated from the FVB WT strain by gene
targeting in embryonic stem cells as described previously [1]. The ani-
mals were kindly provided by Dr. P. Borst (Netherlands Cancer
Center, Amsterdam, The Netherlands). The study plan was approved
by the Animal Care and Use Committee of the University of Trieste.
Embryos were collected at 13th day of pregnancy, and the MEF
were prepared either from WT or Mrp1 knockout mice as described
previously [15]. The cells were cultured under standard conditions, un-
der 5% CO2 and 95% O2, in Dulbecco’s modiﬁed Eagle’s high glucose
medium (DMEM/high, Euro-lone No. EC M0106L) supplemented
with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, and 1% (v/v)
penicillin–streptomycin (100000 units/l penicillin and 100 mg/l strepto-
mycin) at 37 C.
In order to conﬁrm the eﬀective absence of Mrp1 expression in MEF
(/), a Western blot analysis was performed on the cell lysate of each
cell type. Mrp1 was assayed using the polyclonal monospeciﬁc anti-
Mrp1 A-23 antibody developed in our laboratory [16] (Fig. 1).
2.2. Materials
UCB (Sigma Chemical Co., St. Louis, MO), was puriﬁed as de-
scribed by McDonagh and Assisi [17]. [3H]-UCB (29.25 mCi/mmol)
was biosynthetically labeled in vivo and then highly puriﬁed from
the bilirubin conjugates in bile as described [18]. Chloroform, HPLC
grade, was obtained from Carlo Erba (Milan, Italy). 2,7-Dichloroﬂuo-
rescin diacetate, was obtained from Molecular Probes (Carlsbad, CA,
USA). Fatty acid free human serum albumin (HSA), tetrazolium salts
(methylthiazoletetrazolium, MTT), DMSO, HPLC grade, and all
other reagents and chemicals were purchased from Sigma–Aldrich
Italy (Milan, Italy).
2.3. Cell viability studies
Cells were used after 4 passages and were kept in culture for a week
before being utilized. The day before the experiment MEF Mrp1 (+/+)
and (/) were plated in 24 multiwell plates (Corning Incorporated
Costar 3526) at a density of 12500 cells/cm2. Cell viability assays were
conducted when 70% conﬂuence was attained uniformly in all wells.
The growth medium was discarded, the cells were washed with PBS
at 37 C and then incubated with four diﬀerent concentrations of
UCB. UCB was dissolved in DMSO to a ﬁnal concentration of
5.1 mM and added to DMEM containing 60 lMHSA but no fetal bo-
vine serum. The concentration of free UCB (Bf) was calculated using
previously published aﬃnity constants of UCB for HSA, assuming
that the components of the culture medium did not aﬀect the Bf [19].
The concentration of HSA was kept constant (60 lM), and UCB
was added to yield ﬁnal total concentrations of 9, 43 and 55 lM, giving
UCB/HSA molar ratios of 0.15, 0.72 and 0.92 and estimated Bf levels
of 40, 80 and 140 nM, respectively. Control cells were incubated withFig. 1. Protein expression of Mrp1 in MEF cells from (+/+) (WT) and
(/) (KO) mice (Western blot). The samples are crude homogenates
of Mrp1 (+/+) and (/) MEF cells. 50 lg of protein was loaded in
each lane. The primary antibody used was A-23 antiMrp1 [16] at a
dilution of 1:400.DMEM containing HSA 60 lM and a comparable volume of DMSO,
without FCS or UCB. For time course studies, cells were exposed to
increasing Bf (40, 80, and 140 nM) for 120 and 240 min. For dose–re-
sponse studies, cells were exposed for 240 min to a calculated Bf of 20,
40, 80, and 140 nM. At the end of the incubation period, the medium
containing UCB was discarded and the cells tested for viability by
three diﬀerent methods.
2.4. MTT test
The stock solution of 3(4,5-dimethyltiazo-2-yl)-2,5-diphenyl tetrazo-
lium (MTT) was dissolved in PBS, pH 7.4, at 5 mg/mL. Immediately
before the experiment, the MTT solution was diluted to 0.5 mg/mL
in DMEM/high glucose without phenol red to avoid interferences with
plate reading [20]. The cells were incubated with DMEM containing
MTT for 2 h at 37 C. After incubation, to dissolve MTT formazan
crystals, the medium was replaced with 1 mL HCl, 0.04 M isopropanol
added, and the sample agitated in an orbital shaker for 2 h at 37 C.
After centrifugation (10000 rpm for 3 min), absorbance values at
570 nm were determined in a Beckman DU 640 spectrophotometer.
Results were expressed as percentage of control cells, not exposed to
UCB, which was considered as 100% viability.
2.5. Lactate dehydrogenase release
The presence of lactate dehydrogenase (LDH) in the supernatant
and lysate was measured colorimetrically, using a CytoTox 96
Non-Radioactive Cytotoxicity Assay Kit (Promega, Madison, WI,
USA) following the producer’s instructions. Color intensity was read
at a wavelength of 340 nm in a Beckman DU 640 spectrophotometer.
The results are expressed as percent of total LDH release vs. control
cells.
2.6. Intracellular ATP content
Following incubation with UCB/HSA solutions of the MEF cells
seeded into 96-well microplates at 5000/well, the intracellular ATP con-
tent was measured using the CellTiter-Glo luminescent cell viability
assay (Promega, Madison, WI, USA) based on ATP bioluminescence.
100 lL of CellTiter-Glo reagent was added to each well and contents
mixed for 120 s. The plates were then incubated at ambient tempera-
ture for 10 min following the procedure recommended by the manufac-
turer. The luminescence produced by the luciferase-catalyzed reaction
of luciferin with ATP was detected using a LD 400 Luminescence
detector (Beckman Coulter).2.7. Transport of [3H]-UCB by MEF
MEF Mrp1 (+/+) and (/), grown to conﬂuence, and then washed
with DMEM without FCS, as described above for the cell viability
studies, and accumulation of [3H]-UCB determined.
[3H]-UCB (29.25 mCi/mmol) was dissolved in DMSO and diluted
with DMEM containing 60 lM of HSA. The ﬁnal solutions contained
no more than 0.6% v/v DMSO, and unbound UCB concentrations (Bf)
of 40, 80 and 140 nM, calculated as described above [19]. The uptake
of UCB at 37 C was measured 4 h after the addition of 0.5 mL of the
DMEM containing [3H]-UCB to the cell culture. After 4 h, transport
was stopped by removing the incubation medium and washing twice
with ice cold PBS. The cells were lysed for 90 min in 1.0 mL of NaOH
0.2 N containing SDS 2%. The remaining cells were removed from the
well using a cell scraper (Corning Costar Cat no. 3010). A 15 lL ali-
quot of cell lysate was used for measurement of protein concentration,
while the remainder was diluted in 8 mL of liquid scintillation cocktail
for radioassay (Filter counter, Packard Bioscience, Groningen, The
Netherlands). Radioactivity was measured in a liquid scintillation
spectrometer (Beta V, Kontron, Milan, Italy) with automatic quench
corrections using external reference standards and expressed in dpm.
The quantity of [3H]-UCB retained by cells was calculated using the
following equation:
dpm/[(specific activityMW of UCB 106Þ
 (cell proteins(mg/mL) lL utilized 103Þ
¼ pmol UCBmg prot1
To correct for non-speciﬁc binding of [3H]-UCB to the cell mem-
branes, radioactivity on MEF cells exposed to the same [3H]-UCB
solution for 1 min was subtracted from the 4 h value.
S. Calligaris et al. / FEBS Letters 580 (2006) 1355–1359 13572.8. Statistical analysis
Results are expressed as means ± S.D. Each data point represents
the average of three measurements each on at least three separate cell
preparations (n P 9). Diﬀerences between groups were compared
using the paired two-tailed Student’s t test and P < 0.05 was consid-
ered statistically signiﬁcant.3. Results
3.1. Eﬀect of Bf on cell viability
Fig. 2 shows the dose-dependent eﬀect on cell viability of the
exposure for 240 min of Mrp1 (+/+) and (/) MEF to four
diﬀerent levels of Bf, as assessed by the MTT test of mitochon-
drial function. Both cell types revealed a signiﬁcant loss of
about 20% of MTT activity at Bf levels of 40 nM but not
20 nM. At higher Bf levels of 80 and 140 nM, above the aque-
ous solubility of UCB (70 nM), MTT activity decreased fur-
ther in the Mrp1 (/) cells (to 56% of control at
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Fig. 2. Eﬀect of bilirubin on MEF cell viability. MTT test. The cells
were exposed for 4 h to four diﬀerent Bf, and viability then assessed by
the MTT test. (m) MEF cells from Mrp1 (/) KO mice. (h) MEF
cells from Mrp1 (+/+) WT mice. *P < 0.01 for UCB-treated cells vs.
control cells; # = P < 0.01 and #1 = P < 0.02 for Mrp1 (/) vs. Mrp1
(+/+) MEF cells.
Table 1
Eﬀect of bilirubin on cell viability: MTT test time course
Time (min.) Bf (nM)
40 nM 80 nM
WT KO WT
0 100 ± 3.7 100 ± 5.8 100 ± 3.7
120 92.6 ± 3.6 86.2 ± 4.1 90.3 ± 2.0
240 87.4 ± 6.4 84.5 ± 1.0a 84.7 ± 3.7a
Mrp1 (+/+) (WT) and Mrp1 (/) (KO) MEF cells were exposed to four d
aP < 0.01 for treated cells vs. control cells.
bP < 0.01 for MEF Mrp1 / vs. MEF +/+.cells (P < 0.01). In both types of cells at all Bf levels, the de-
crease in MTT activity increased with the duration of exposure
to UCB, but the decline in MTT activity was greater for the
Mrp1 KO cells than the WT cells at any given dose or exposure
time (Table 1).
As shown in Fig. 3, increased LDH release paralleled the
loss of viability revealed by the MTT test. No signiﬁcant in-
crease in LDH release was observed at Bf values of 20 or
40 nM, whereas enzyme release increased signiﬁcantly and pro-
gressively when the Bf was raised to levels slightly (80 nM) or
substantially (140 nM) above aqueous solubility. Above the
solubility limit of UCB (70 nM), LDH release was signiﬁcantly
higher in Mrp1 (/) cells and, at Bf = 140 nM, was almost
double the release by Mrp1 (+/+) WT cells (P < 0.005).
Table 2 shows that exposure of Mrp1 (/) KO cells to
increasing Bf for 4 h caused a dose-related decrease in the
intracellular content of ATP when Bf exceeded its aqueous sol-
ubility limit of 70 nM, but did not signiﬁcantly decrease intra-
cellular ATP levels in the (+/+) WT cells.
Collectively these data indicate a greater susceptibility of
(/) KO cells than (+/+) WT cells to be damaged by
short-term exposure to Bf, especially at Bf levels exceeding
the aqueous solubility limit of 70 nM.140 nM
KO WT KO
100 ± 5.8 100 ± 3.7 100 ± 5.8
85.4 ± 2.0 80.6 ± 1.1a 69.1 ± 1.4a,b
74.4 ± 2.9a,b 74.2 ± 3.2a 58.3 ± 2.9a,b
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Fig. 3. Eﬀect of bilirubin on cell viability. LDH release. The cells were
exposed for 4 h to four diﬀerent Bf, and viability assessed by the
fraction of cellular LDH released into the medium. Symbols for groups
and for P-values as in Fig. 2.
Table 2
Eﬀect of bilirubin on cellular ATP levels
Bf (nM) ATP levels, % of control
WT KO
0 100 ± 4 100 ± 5
40 101 ± 5 97.3 ± 2.8
80 102 ± 1.6 86.9 ±5.0a,c
140 96.7 ± 4.2 71.4 ± 2.6a,b
Mrp1 (+/+) (WT) and Mrp1 (/) (KO) MEF cells were exposed to
four diﬀerent Bf for 4 h and the cellular ATP concentration then
determined.
aP < 0.01 treated cells vs. control cells.
bP < 0.01 MEF Mrp1 / vs. MEF +/+.
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Fig. 4. [3H] Bilirubin uptake. MEF cells were incubated with [3H]-
UCB (sp. act. 29.25 mCi/mmol) for 4 h. Black bars = MEF cells from
Mrp1 (/) KO mice. White bars = MEF cells from Mrp1 (+/+) WT
mice. *P < 0.01 for UCB-treated cells vs. control cells; # = P < 0.01
and #1 = P < 0.03 for Mrp1 (/) vs. Mrp1 (+/+) MEF cells.
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Fig. 4 shows that the cellular accumulation of [3H]-UCB in-
creased linearly with exposure to increasing Bf. However, at all
three Bf levels tested, the intracellular accumulation of [3H]-
bilirubin after 4 h was consistently about twice as great in
(/) KO cells as in (+/+) WT cells (P < 0.01).4. Discussion
Mrp1 has been demonstrated to transport UCB which has
the highest aﬃnity of any substrate so far reported for this
ABC transporter [13]. In addition, Mrp1 has been shown to
be relocated from the Golgi to the cell membrane when mouse
astrocytes are exposed to UCB [14], suggesting a protective ef-
fect of the ABC protein linked to its ability to export the pig-
ment extracellulary. However, direct evidence is lacking for a
functional role of Mrp1 in protecting cells from UCB toxicity.
Immunoblotting of the Mrp1 (/) KO MEF cells con-
ﬁrmed the absence of Mrp1. This was associated with a signif-
icantly greater susceptibility than Mrp1 (+/+) MEF cells to
toxicity from UCB, manifested by impaired mitochondrialfunction (MTT test), increased cellular permeability (LDH re-
lease) and loss of intracellular ATP. Conﬁrming in vitro ﬁnd-
ings with neurones and astrocytes [8], this greater susceptibility
was uniformly evident at calculated free UCB concentrations
(Bf) which were slightly or well above the aqueous solubility
of UCB (70 nM). It should be emphasized that these calculated
Bf values were derived from Kf values obtained with a diﬀerent
batch of HSA in a simpler, cell-free medium [19]; therefore, if
any ingredients of the DMEM/high used in the present dis-
place UCB from HSA, these calculated Bf values may be fal-
sely, but proportionately low. The validity of simpler
techniques used to measure Bf in serum/plasma [21] have not
yet been validated in culture media.
No diﬀerences in MTT activity or LDH release were ob-
served between Mrp1 (/) KO and Mrp1 (+/+) WT cells at
Bf up to 40 nM, even though decreased mitochondrial function
(assessed by MTT test) became evident in both cell types at this
Bf level.
In addition to a direct eﬀect on mitochondrial function and/
or to membrane permeability, exposure to UCB signiﬁcantly
decreased the ATP levels in Mrp1 (/) KO cells when the
Bf was 140 nM. Interestingly, unlike the impaired MTT activ-
ity and increased LDH release, exposure of Mrp1 (+/+) WT
cells to Bf of 80 and 140 nM for 4 h was not associated with
a decrease in intracellular ATP. This indicates that the de-
crease in mitochondrial function and increase in cellular per-
meability induced by UCB at these Bf levels is not mediated
by depletion of cellular ATP.
MTT activity was progressively impaired with increasing
duration of exposure to UCB, particularly in the Mrp1
(/) KO cells. This suggested that the greater toxic eﬀect of
UCB in Mrp1 (/) KO cells might be related in part to their
lack of cellular export of UCB by Mrp1, allowing a greater
intracellular accumulation of UCB. This was supported by
our direct measurement of the cellular uptake of [3H]-UCB,
demonstrating that cellular accumulation of UCB at each Bf
was about twice as great in the Mrp1 KO cells than in the
WT cells. This extends our prior observations that impairment
of cellular MTT activity and increased LDH release on expo-
sure to UCB was greatly enhanced by treatment of cultured
astroglial cells with MK581, a general inhibitor of Mrp’s [14].
The dose-related eﬀects on toxicity paralleled the UCB up-
take only when Bf was above 70 nM, in keeping with our prior
observations [8] that cytotoxicity of neurones and astrocytes
seemed to occur only when Bf exceeded the aqueous solubility
limit of UCB. In the studies of Gennuso et al. [14], however,
cytotoxicity was observed even at Bf = 40 nM when Mrp1
was inhibited. In the present study, in the absence of inhibitors
of Mrp1, MEF cells likewise exhibited impaired mitochondrial
function (MTT test) at Bf = 40 nM. These observations indi-
cate that the free intracellular concentration of UCB is the ulti-
mate determinant of toxicity, albeit itself related to the
extracellular Bf. In the present study, the total cellular [3H]-
UCB content in the Mrp1 (/) KO cells reached levels as
high as 200 pmol/mg protein, only a small fraction of which
was likely unbound.
Since UCB can diﬀuse into any cell [22] and is a potent anti-
oxidant at low concentrations but toxic at high concentrations
[23], all cells must maintain the intracellular concentration of
UCB below toxic concentrations. This is regulated by con-
sumption (conjugation and oxidation), and export of the
UCB [8]. Since, unlike hepatocytes, most cells do not possess
S. Calligaris et al. / FEBS Letters 580 (2006) 1355–1359 1359conjugation activity, they have to oxidize or export UCB to
prevent its intracellular accumulation. We have shown that
this export of UCB is in part accounted for by the activity
of MRP1/Mrp1. Several studies from Watchko’s laboratory
[24–26] indicate that MDR1 may play a similar role, albeit
possibly only at higher UCB concentrations.
We conclude that Mrp1 has an active role in the protection
of MEF cells against bilirubin toxicity. This ﬁnding reinforces
the concept that ATP dependent export of bilirubin is an
important cellular mechanism to maintain intracellular un-
bound bilirubin levels at non-toxic, low nanomolar concentra-
tions. We speculate that diﬀerences in the activity of MRP1/
Mrp1 and/or MDR1 may explain the marked diﬀerences in
the susceptibility to UCB toxicity among diﬀerent cells and
in the incidence kernicterus among diﬀerent parts of the CNS.
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